Renaissance Capital logo

SNDX News

Renaissance Capital's 1Q16 US IPO Market Review

EDIT

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

Syndax Pharmaceuticals prices IPO at $12, well below the range

SNDX

Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, raised $53 million by offering 4.4 million shares at $12, below the range of $14 to $16. Syndax Pharmaceuticals plans to list on the Nasdaq under the symbol SNDX. Morgan Stanley and Citi acted as lead managers on the deal....read more

Week ahead: IPO market still stuck in neutral

SNDX

The IPO market remains in the doldrums this week, but the Renaissance IPO Index's 10% gain in the past two weeks suggests that the IPO train could start rolling again in March. Second time's a charm After a scrapped IPO attempt in June 2014, Syndax Pharmaceuticals (SNDX) has shifted its business focus after discovering new indications for its...read more

Second time's a charm: Syndax Pharmaceuticals sets terms for $66 million IPO

SNDX

Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $66 million by offering 4.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Syndax Pharmaceuticals would command a fully diluted market value of $285...read more